High-throughput virtual screening of phenylpyrimidine derivatives as selective JAK3 antagonists using computational...

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
• Janus Kinase 3 (JAK3) is a critical tyrosine kinase in immune cell signaling pathways and a therapeutic target for RA.
• Phenylpyrimidine derivatives have shown biological activity and are promising candidates for drug development.

Purpose of the Study:

• To identify novel phenylpyrimidine derivatives with potent JAK3 inhibitory activity for potential rheumatoid arthritis treatment.
• To develop and validate a pharmacophore model for guiding the design of new JAK3 inhibitors.
• To computationally assess the pharmacokinetic properties, binding affinity, and synthetic feasibility of lead compounds.

Main Methods:

• Pharmacophore modeling using 39 phenylpyrimidine derivatives with high experimental pIC50 values.
• 3D-Quantitative Structure-Activity Relationship (3D-QSAR) studies (atom-based and field-based) for model validation.
• Covalent docking, molecular dynamics (MD) simulations, and MM/GBSA calculations to assess binding and stability.
• ADME-Tox predictions to filter compounds with potential adverse effects.
• Retrosynthesis analysis for evaluating synthetic accessibility.

Main Results:

• A five-point pharmacophore model (DHRRR_1) was generated, highlighting key features for JAK3 inhibition.
• Validated 3D-QSAR models (atom-based: R2=0.95, Q2=0.67; field-based: R2=0.93, Q2=0.76) accurately predicted compound activity.
• The pharmacophore model successfully distinguished active from inactive compounds (ROC=0.77) and identified potential JAK3 inhibitors.
• Molecular simulations confirmed the stability and binding affinity of selected derivatives to JAK3.
• A synthetic pathway was proposed for the identified lead compounds.

Conclusions:

• Phenylpyrimidine derivatives represent a promising class of JAK3 inhibitors for rheumatoid arthritis therapy.
• The developed pharmacophore and 3D-QSAR models provide a robust framework for designing optimized JAK3 inhibitors.
• Computational approaches, including molecular dynamics and retrosynthesis, are valuable for accelerating drug discovery and development.